EuroBiotech: More Articles of Note


> A leading British fund selector has reportedly pulled close to £300 million ($400 million) from one of Neil Woodford’s investment vehicles. The fund selector, Jupiter Asset Management, followed Woodford from Invesco Perpetual to his own startup investment outfit. But, against a backdrop of setbacks for Woodford’s portfolio companies, is said to have reduced its exposure to his flagship fund. Financial Times article

> Azura Ophthalmics raised $16 million to advance its treatment for meibomian gland dysfunction deeper into the clinic. OrbiMed, TPG Biotech and Brandon Capital led the investment in the Israeli biotech. Release

> Abingworth invested in VirionHealth. The British biotech will use the £13 million ($17 million) series A round to advance drugs that prevent and treat viral infections by outcompeting replication of the pathogens. Statement


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> ObsEva set up a $60 million private placement. The Swiss biotech expects to tap existing investors including New Enterprise Associates and Sofinnova Ventures for the cash. ObsEva is offering stock at $8 a pop, well below the $15 price it went public at earlier this year. Release  

> Kiadis Pharma raised €18 million ($21 million). The European biotech will use the money to fund a phase 3 trial of its lead candidate, ATIR101. Statement

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.